[ ] [ ] [ ] [ ] [ ] [ ] [ ] 1 6.5 2017 12,090 2030 24,570 2017 1,106 9.1% 139
2030 4,068 16.6% 2013 2030 7.3% 7.6% 7.5% 8.1% 72.9 79.2 83.2 93.7 9.1% 110.6 10.1% 128.3 11.0% 147.6 11.8% 166.8 13.1% 12.6% 12.2% 220.9 201.8 183.4 13.6% 242.6 14.0% 14.4% 265.2 289.0 14.9% 316.5 15.6% 348.1 16.1% 16.6% 376.0 406.8 140
2017 2,201 2030 5,361 141
2013 8.4% 2017 9.7% 13.7% 2017 214 2017 2030 2030 1,006 18.8% 2013 2030 8.4% 8.7% 9.0% 9.4% 9.7% 10.1% 12.8 15.0 16.9 19.2 21.4 24.0 10.7% 11.3% 27.3 31.4 11.9% 35.7 13.7% 13.5% 12.1% 13.1% 12.5% 45.5 40.3 15.3% 64.6 57.4 51.2 16.3% 72.7 17.1% 17.9% 81.4 90.4 18.8% 100.6 Chen et al. 2016 2015 430 280 2015 57% 2014 2030 550 142
2014 Chen 2014 2018 30(1):1-12 2017 10 8 143
2017 2 2017 14 30 81 10% 30% 36 44% 2017 TAGRISSO SUTENT ABRAXANE ZELBORAF 2016 7.93 2030 9.92 57.3% 68.0% 10% 30% 144
5ml:30mg 747 5ml:30mg 155 0.5ml:18mg 1523 0.5ml:18mg 284 0.5ml:18mg 367 0.1g 5755 0.1g 2680 0.025g 75 0.2g 39 0.2g 38 0.5g 23 0.5g 30 0.5g 38 0.5g 33 0.2g 426 0.2g 190 0.2g 185 0.25g 34 0.25g 35 10ml:0.25g 2 10ml:0.25g 2 0.25g 34 0.25g 30 145
25mg 1102 25mg 944 25mg 2 25mg 5 1.0mg 25mg 2344 2 1.0mg 25mg 1725 5 0.125g 67 0.2g 292 0.25g 236 0.25g 166 0.2g 750 50ml:0.5mg 8299 2000 2017 2017 2 BTK NHL (HL) B T B 85% B (U.S. National Cancer Institute) (Surveillance, Epidemiology and End Results (SEER)) 2017 72,240 20,140 20,110 CLL 4,660 GLOBOCAN 2012 Chen et al. 2016 42,000 88,000 26,000 53,000 CD20 BTK PI3K idelalisib copanlisib Bcl-2 venetoclax YESCARTA B (DLBCL) YESCARTA CD-19 T 146
BTK BTK B BTK B (BCR) BTK B 2018 7 18 BTK IMBRUVICA CALQUENCE (acalabrutinib) 2013 2013 17p CD20 80 Acalabrutinib 2017 10 2017 11 IMBRUVICA 2018 7 18 BTK BTK 2017 BTK 2014 1 32 2030 178 BTK 2014 2030 Evaluate Pharma 147
BTK IMBRUVICA 2017 11 BTK 2030 16 BTK 2017 2030 176.6% 12.9% 1.3 1.3 1.4 1.5 1.6 1.6 1.1 0.9 0.6 0.4 0.0 0.0 0.1 0.2 PD-1/PD-L1 2017 138 73.2% 2030 1,390 2030 34.3% 2017 1.4 2030 185 2030 18.4% PD-1/PD-L1 T T 148
PD-1 T PD-L1 PD-1 PD-L1 PD-1 T PD-L1 PD- L1 T PD-1 PD-L1 PD-L1 PD-1 T PD-1/PD-L1 PD-1 KEYTRUDA (pembrolizumab) OPDIVO (nivolumab) PD-L1 TECENTRIQ (atezolizumab) IMFINZI (durvalumab) BAVENCIO (avelumab) PD-1/PD-L1 tislelizumab cemiplimab PDR-001 Tesaro TSR042 PF-06801591 KEYTRUDA OPDIVO chl HNSCC UC OPDIVO KEYTRUDA MSI TECENTRIQ IMFINZI BAVENCIO Merkel PD-1/PD-L1 2017 PD-1/PD-L1 101 PD-1/PD-L1 2030 789 PD-1/PD-L1 2014 2017 2018 2030 PD-1 PD-L1 2014 2030 149
PD-1/PD-L1 PD-1 2012 38% 45% 51% 49% PD-1/PD-L1 Chen et al. 2016 PD-1/PD-L1 SEER PD-1/PD-L1 2015 (GLOBOCAN) 2015 (Chen et al.) 2017 SEER PD-1/PD-L1 150
PD-1/PD-1 EGFR ALK VEGFR 2018 6 15 PD-1 OPDIVO (nivolumab) PD-L1 2018 6 15 OPDIVO (nivolumab) EGFR ALK 2018 6 15 PD-1 2018 2 pembrolizumab 2018 3 JS001 (trepinzumab) IBI308 (sintilimab) 2018 4 SHR-1210 (camrelizumab) 151
PD-1/PD-L1 PD-1/PD-L1 2030 151 PD-1 PD-L1 2018 2030 534.4% 498.7% 455.2% 12.8% -0.1% 31.4% 10.8 12.1 12.8 13.5 4.5 14.0 4.3 14.6 4.4 15.1 4.5 8.6 5.8 5.4 0.0 0.0 2.3 0.7 0.2 2.0 0.2 0.6 0.0 0.1 0.8 5.8 4.6 1.2 6.1 2.6 6.3 4.5 6.2 7.4 9.0 9.7 10.2 10.6 PARP PARP PARP PARP1 PARP2 DNA PARPs DNA DNA BRCA1/2 PARP PARP PARP PARP DNA PARP DNA PARP PARP OC PARP SEER 22,440 252,710 161,360 28,000 Chen et al. 2016 52,000 272,000 60,000 680,000 152
PARP PARP LYNPARZA (olaparib) Clovis Oncology RUBRACA (rucaparib) Tesaro ZEJULA (niraparib) PARP pamiparib veliparib talazoparib 2018 7 18 PARP olaparib (Zai Lab) niraparib 1 3 PARP pamiparib fluzoparib PARP 2017 PARP 4.61 LYNPARZA 2017 2.97 PARP 2030 123 PARP PARP 2015 2030 Evaluate Pharma 153
PARP 2030 13 PARP PARP 2018 2030 272.2% 12.8% 0.8 0.9 1.0 1.1 1.1 1.2 1.2 1.3 0.5 0.0 0.0 0.1 0.2 (i)tislelizumab zanubrutinib 3.2 0.4 (ii) tislelizumab zanubrutinib pamiparib 1.6 0.08 0.05 154
Product Zanubrutinib Tislelizumab Pamiparib GloboCan Product Zanubrutinib Tislelizumab Pamiparib GloboCan 155
[ ] 1961 [ ] [ ] 680,000 [ ] [ ] 156